Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model.
<h4>Background</h4>The immunosuppressive mammalian target of rapamycin (mTOR) inhibitors are widely used in solid organ transplantation, but their effect on kidney disease progression is controversial. mTOR has emerged as one of the main pathways regulating cell growth, proliferation, di...
Guardado en:
Autores principales: | Melania Kurdián, Inmaculada Herrero-Fresneda, Nuria Lloberas, Pepita Gimenez-Bonafe, Virginia Coria, María T Grande, José Boggia, Leonel Malacrida, Joan Torras, Miguel A Arévalo, Francisco González-Martínez, José M López-Novoa, Josep Grinyó, Oscar Noboa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/af232cd236874a11ba395d91515663ac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Chun-Ting Kuo, et al.
Publicado: (2019) -
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Khashayar Esfahani, et al.
Publicado: (2019) -
Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
por: Cong Luo, et al.
Publicado: (2021) -
The Fibrotic Effects of TMAO on Human Renal Fibroblasts Is Mediated by NLRP3, Caspase-1 and the PERK/Akt/mTOR Pathway
por: Stefania Kapetanaki, et al.
Publicado: (2021) -
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Chris Coppin
Publicado: (2010)